Urology Devices Market - Global Forecast 2025-2032

The urology devices market is advancing rapidly as healthcare decision-makers navigate a landscape shaped by new technologies, evolving care models, and an increasing focus on value-driven solutions. In this climate, leaders must balance innovation adoption with operational effectiveness to realize sustainable progress.

Market Snapshot: Urology Devices Market Size and Growth Outlook

The urology devices market continues its robust expansion, moving from USD 44.41 billion in 2024 to USD 48.56 billion in 2025. Long-term projections indicate that sector value will reach USD 91.88 billion by 2032, underpinned by a compound annual growth rate of 9.51%. This growth stems from increased demand for minimally invasive therapies and accelerated adoption of digital diagnostics within urology. Evolving healthcare delivery models are prioritizing patient-centered care, while demographic changes broaden the population requiring urological services. Regulatory transitions and persistent supply chain challenges underscore the necessity for organizational agility and strategic foresight to remain competitive in a complex global market.

Scope & Segmentation of the Urology Devices Market

This report offers senior executives targeted market intelligence designed to inform effective strategic planning by segment and region. The analysis provides insight into technology trends, procurement dynamics, and shifting care delivery frameworks across several core dimensions:

• Product Type: Covers continence management solutions, penile prostheses, and a variety of endoscopic instruments, including cystoscopes, nephroscopes, and ureteroscopes. The segment also includes devices for stone management, a wide selection of ureteral stents, and advanced urodynamic systems supporting diagnostics and patient monitoring.
• Technology Platform: Examines the balance between disposable and reusable devices, assessing implications for workflows, cost structures, and procurement preferences within diverse clinical environments.
• Application Area: Addresses use cases in benign prostatic disease, oncology, urinary incontinence, kidney stone interventions, and infection management, reflecting the broad utility of modern urology device portfolios.
• End User: Reviews adoption patterns and decision criteria among hospitals, ambulatory surgical centers, and specialty practices—emphasizing differences in procurement approaches and user needs.
• Geography: Delivers context-specific intelligence across the Americas, Europe, Asia-Pacific, the Middle East, and Africa. Evaluation includes regional regulatory trends, health system structures, and logistical factors impacting adoption.
• Industry Participants: Features profiles and strategies of leading manufacturers, such as Boston Scientific Corporation, Johnson & Johnson, Olympus Corporation, Medtronic plc, Stryker Corporation, Teleflex Incorporated, Coloplast A/S, Cook Medical LLC, KARL STORZ SE & Co. KG, and Richard Wolf GmbH, highlighting their market positioning and innovation pathways.

Key Takeaways for Senior Decision-Makers

• Increasing preference for minimally invasive treatments and greater awareness of chronic urinary conditions are revising care delivery standards for both providers and payers.
• Emerging digital solutions, including artificial intelligence in diagnostics and remote patient monitoring, are creating new opportunities for workflow optimization and patient engagement.
• Device manufacturers are reshaping compliance frameworks to respond to evolving regulations, especially surrounding software-enabled and connected technologies.
• Collaborative innovation—driven by partnerships among manufacturers, pharmaceutical companies, and research institutions—is accelerating product development and facilitating market entry of new solutions.
• Procurement teams are implementing value-based assessment models to extract greater ROI from capital investments and optimize device lifecycle management across care settings.

Tariff Impact: Strengthening the Urology Device Supply Chain

Recent introductions of U.S. tariffs have prompted manufacturers to diversify sourcing strategies and establish new local supplier relationships, mitigating exposure to cost volatility. These efforts are making the urology device supply chain more resilient and responsive to potential disruptions. Organizations are also investing in regional production and simplifying regulatory pathways to sustain competitiveness throughout evolving global trade dynamics.

Methodology & Data Sources

This report constructs its findings through a blend of primary and secondary market research. Key inputs include regulatory disclosures, peer-reviewed studies, proprietary clinical outcomes, and direct insights from industry professionals—including clinicians and procurement leaders. These combined sources enhance the depth, accuracy, and relevance of the report’s intelligence.

Why This Report Matters

• Equips decision-makers with actionable segmentation analysis to streamline procurement and adapt to market trends.
• Provides critical context for designing robust supply chain and compliance strategies that address the realities of the global marketplace.
• Enables leadership teams to identify growth levers, strengthen risk management, and build collaborative models aligned with evolving industry expectations.

Conclusion

Senior leadership teams that embrace technology modernization, forward-thinking procurement, and strategic collaboration will be prepared to address sector changes and drive progress in the urology devices market.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.